VEGFA and myocardial ischemia: These effects of anti‐VEGF‐A therapies have been reported to precipitate clinical adverse reactions in some patients, including hypertension, increased risk of hemorrhage or thromboembolic events, or cardiac ischemia (Kamba & McDonald, 2007).